Found 246 clinical trials
Assessment of Safety, Tolerability, and Efficacy Measured by Amyloid Reduction of LY3372993 in Early Symptomatic Alzheimer's Disease
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's disease (AD).
- 0 views
- 24 Oct, 2022
- 74 locations
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
216 weeks of treatment (A45 Trial) and to determine whether treatment with BAN2401 is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography
- 26 views
- 29 Aug, 2022
- 4 locations
Valacyclovir for Mild Cognitive Impairment (VALMCI)
Anti-viral treatment in Mild Cognitive Impairment (MCI) is a Phase II, placebo-controlled, 52-week trial using oral valacyclovir 4 g/day in 50 HSV seropositive, AD biomarker-positive, amnestic mild cognitive impairment (MCI) patients (eMCI and lMCI). The trial will directly address the long-standing viral etiology hypothesis of Alzheimer's disease (AD) which posits …
- 47 views
- 08 Sep, 2022
- 1 location
A PHASE III, MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GANTENERUMAB IN PARTICIPANTS AT RISK FOR OR AT THE EARLIEST STAGES OF ALZHEIMER’S DISEASE
This study is designed to evaluate the efficacy and safety of Gantenerumab in participants at risk for or at the earliest stages of Alzheimer’s Disease (AD)
- 4 views
- 24 Jun, 2022
- 1 location
B3461087 - Tafamidis
This study is a global, multi-center study designed to estimate the global prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) within a clinically at risk population [participants with
- 0 views
- 09 Jun, 2022
- 5 locations
Impact of sleep apnea and its treatment on memory and tau accumulation in the brain
may be a modifiable risk factor for AD. This study will build on that by evaluating the effect of PAP treatment on markers of AD, such as amyloid beta (Aβ), Tau levels, and neurofilament light chain
- 0 views
- 25 Mar, 2022
- 1 location
Proteins and Brain Networks in Atypical Alzheimer's Disease
Participants will take part in 2-4 study visits including detailed history and neurological exam, pen-&-paper cognitive testing, and functional MRI and PET scans designed to help us understand how different forms of Alzheimer's disease affect brain circuits over time.
- 53 views
- 24 Jan, 2022
- 1 location
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
- 87 views
- 25 Mar, 2021
- 1 location
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
- 258 views
- 08 Dec, 2020
- 1 location
Cognitive Impairment Registry
The purpose of this study is to develop a recruitment registry of potential drug study participants who may have amyloid, a specific biomarker for Alzheimer's disease, using a phone assessment
- 1069 views
- 23 Sep, 2022
- 1 location
- Online study